HC Wainwright Reiterates “Buy” Rating for Halozyme Therapeutics (NASDAQ:HALO)

HC Wainwright reaffirmed their buy rating on shares of Halozyme Therapeutics (NASDAQ:HALO) in a research note issued to investors on Tuesday morning,Benzinga reports. They currently have a $70.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on HALO. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a report on Friday, January 10th. Wells Fargo & Company decreased their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, JMP Securities boosted their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $60.89.

Halozyme Therapeutics Trading Up 0.9 %

Shares of HALO stock opened at $56.77 on Tuesday. Halozyme Therapeutics has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The stock has a market cap of $7.22 billion, a price-to-earnings ratio of 18.80, a PEG ratio of 0.43 and a beta of 1.25. The stock has a 50-day moving average of $51.00 and a 200-day moving average of $54.35.

Insider Activity at Halozyme Therapeutics

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Heck Capital Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $29,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 67.7% in the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after purchasing an additional 350 shares during the last quarter. Toth Financial Advisory Corp bought a new position in shares of Halozyme Therapeutics in the third quarter valued at approximately $57,000. FSC Wealth Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the third quarter valued at approximately $65,000. Finally, Park Place Capital Corp grew its holdings in Halozyme Therapeutics by 828.1% during the third quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,209 shares in the last quarter. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.